Table 1.
ECM
|
Alterations in COVID-19
|
Suggested ECM role in disease
|
In other inflammatory and fibrotic lung disorders
|
MMP-1 | Increased MMP-1 levels have been detected in the serum of patients, which correlated with the severity of COVID-19 and early fibrosis with this condition[23] | Drive endothelial cell destruction, such as by over-activating the mmp-1/PAR1 pathway, increasing VEGF-2 receptor expression, and causing endothelial damage. Involved in collagen deposition in IPF | Emphysema, Asthma: MMP-1 levels raised |
MMP-2 | Increased MMP-2 levels have been detected in the CSF samples of COVID-19 patients with neurological syndrome[30]. Downregulated MMP-2 levels have been detected in the plasma samples with this condition, which correlated with the mortality rate of COVID-19[31] | Involved in disruption of the blood-brain barrier. Being Involved in the regulation of angiogenesis may lead to vascular remodeling. Play an anti-inflammatory effect in the endothelial dysfunction | Asthma, Idiopathic Pneumonia: MMP-2 levels raised. pulmonary fibrosis (IPF): Disproportionate extracellular matrix degradation |
MMP-3 | Increased MMP-3 levels have been detected in serum of individuals with this condition[37,40] | Associated with activation of MMP-9 and enhanced synthesis of procollagen | Asthma: MMP-3 levels raised |
MMP-7 | Increased MMP-7 levels have been detected in the serum of obese-diabetic patients with novel coronavirus pneumonia-infected[36]. Elevated in COVID-19 patients with early fibrotic changes[27] | Contribute to airway epithelial damage and inflammation as well as Play a profibrotic effect | Asthma, Cystic fibrosis (CF), ARDS: MMP-7 levels raised |
MMP-8 | / | / | COPD, Emphysema, Asthma: MMP-8 levels raised |
MMP-9 | Increased MMP-9 levels have been detected in the circulation of COVID-19 patients with respiratory failure and with obese-diabetic[36] | Associated with respiratory failure. Linked to inflammation-induced tissue remodeling. Contributes to the disruption of alveolar epithelial basement membrane | COPD, Emphysema, Asthma, IPF, UIP, ALI, ARDS: MMP-9 levels raised |
MMP-10 | The CSF levels of MMP-10 correlated with the degree of neurologic dysfunction exhibited[41] | Associated with neurodegeneration | / |
MMP-12 | / | / | COPD, Emphysema: MMP-12 levels raised |
MMP-14 | Increased MMP-14 levels in lung tissue have been detected COVID-19 patients[32] | Implicated in COVID-19 pathogenesis | COPD: MMP-14 levels raised |
HA | Increased HA levels have been detected in lungs of deceased COVID-19 patients[13]. HA fragments present at elevated levels in COVID-19 patient plasma[16] | Induce endothelial barrier dysfunction | ARDS: HA levels raised |
Proteogly-cans | / | / | COPD, IPF, Asthma, Bronchiolitis obliterans syndrome: Versican levels raised |
Collagen | 16 collagens are downregulated or diminished in COVID-19[52]. Collagen deposits on Lung Samples of deceased COVID-19 patients[51] | Damage of mechanical characteristics of lungs | Asthma, COPD, IPF: Display differing collagen deposition |
ADAMs | Increased ADAM12 and ADAM17 levels have been detected in serum of COVID-19 patients[56-58] | ADAM17 may be associated with viral entry. ADAM12 plays a role in inflammation and endothelial cell permeability | / |
ADAMTS | ADAMTS13 decreased significantly with increasing COVID-19 severity[59,60] | Associated with vascular microthrombotic disease | / |
COVID-19: Coronavirus disease 2019; ALI: Acute lung injury; ARDS: Adult respiratory distress syndrome; COPD: Chronic obstructive pulmonary disease; ECM: Extracellular matrix; HA: Hyaluronan; MMP: Matrix metalloproteinase; IPF: Idiopathic pulmonary fibrosis; UIP: Usual interstitial pueumonia; VEGF-2: Vascular endothelial growth factor 2.